Your browser doesn't support javascript.
loading
Vaccine Effectiveness Against SARS-CoV-2 Related Hospitalizations in People who had Experienced Homelessness or Incarceration - Findings from the Minnesota EHR Consortium.
DeSilva, Malini B; Knowlton, Gregory; Rai, Nayanjot K; Bodurtha, Peter; Essien, Inih; Riddles, John; Mehari, Lemlem; Muscoplat, Miriam; Lynfield, Ruth; Rowley, Elizabeth Ak; Chamberlain, Alanna M; Patel, Palak; Hughes, Alexandria; Dickerson, Monica; Thompson, Mark G; Griggs, Eric P; Tenforde, Mark; Winkelman, Tyler Na; Benitez, Gabriela Vazquez; Drawz, Paul E.
Afiliação
  • DeSilva MB; Health Partners Institute, 8170 33rd Ave South, Mail stop 21112R, Bloomington, MN, 55440-1524, USA. malini.b.desilva@healthpartners.com.
  • Knowlton G; Health Partners Institute, 8170 33rd Ave South, Mail stop 21112R, Bloomington, MN, 55440-1524, USA.
  • Rai NK; Division of Nephrology & Hypertension, University of Minnesota, Minneapolis, MN, USA.
  • Bodurtha P; Health, Homelessness and Criminal Justice Lab, Hennepin Healthcare Research Institute, Minneapolis, MN, USA.
  • Essien I; Health Partners Institute, 8170 33rd Ave South, Mail stop 21112R, Bloomington, MN, 55440-1524, USA.
  • Riddles J; Westat, Rockville, MD, USA.
  • Mehari L; Westat, Rockville, MD, USA.
  • Muscoplat M; Division of Infectious Disease, Epidemiology, Prevention, and Control, Department of Health, St Paul, Minnesota, MN, USA.
  • Lynfield R; Minnesota Department of Health, St Paul, MN, USA.
  • Rowley EA; Westat, Rockville, MD, USA.
  • Chamberlain AM; Mayo Clinic, Rochester, MN, USA.
  • Patel P; Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, GA, USA.
  • Hughes A; Westat, Rockville, MD, USA.
  • Dickerson M; Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, GA, USA.
  • Thompson MG; Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, GA, USA.
  • Griggs EP; Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, GA, USA.
  • Tenforde M; Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, GA, USA.
  • Winkelman TN; Health, Homelessness and Criminal Justice Lab, Hennepin Healthcare Research Institute, Minneapolis, MN, USA.
  • Benitez GV; General Internal Medicine, Department of Medicine, Hennepin Healthcare, Minneapolis, MN, USA.
  • Drawz PE; Health Partners Institute, 8170 33rd Ave South, Mail stop 21112R, Bloomington, MN, 55440-1524, USA.
J Community Health ; 49(3): 448-457, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38066221
ABSTRACT
COVID-19 disproportionately affects people experiencing homelessness or incarceration. While homelessness or incarceration alone may not impact vaccine effectiveness, medical comorbidities along with social conditions associated with homelessness or incarceration may impact estimated vaccine effectiveness. COVID-19 vaccines reduce rates of hospitalization and death; vaccine effectiveness (VE) against severe outcomes in people experiencing homelessness or incarceration is unknown. We conducted a retrospective, observational cohort study evaluating COVID-19 vaccine VE against SARS-CoV-2 related hospitalization (positive SARS-CoV-2 molecular test same week or within 3 weeks prior to hospital admission) among patients who had experienced homelessness or incarceration. We utilized data from 8 health systems in the Minnesota Electronic Health Record Consortium linked to data from Minnesota's immunization information system, Homeless Management Information System, and Department of Corrections. We included patients 18 years and older with a history of experiencing homelessness or incarceration. VE and 95% Confidence Intervals (CI) against SARS-CoV-2 hospitalization were estimated for primary series and one booster dose from Cox proportional hazard models as 100*(1-Hazard Ratio) during August 26, 2021, through October 8, 2022 adjusting for patient age, sex, comorbid medical conditions, and race/ethnicity. We included 80,051 individuals who had experienced homelessness or incarceration. Adjusted VE was 52% (95% CI, 41-60%) among those 22 weeks or more since their primary series, 66% (95% CI, 53-75%) among those less than 22 weeks since their primary series, and 69% (95% CI 60-76%) among those with one booster. VE estimates were consistently lower during the Omicron predominance period compared with the combined Omicron and Delta periods. Despite higher exposure risk, COVID-19 vaccines provided good effectiveness against SARS-CoV-2 related hospitalizations in persons who have experienced homelessness or incarceration.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pessoas Mal Alojadas / COVID-19 Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pessoas Mal Alojadas / COVID-19 Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article